Istradefylline
This adenosine A2A receptor antagonist is used as an add-on therapy in adults with Parkinson's disease experiencing wearing-off episodes with levodopa treatment. It reduces the time patients spend in an "off" state (with return of Parkinson's symptoms) by modulating dopaminergic signaling through the indirect pathway of the basal ganglia. It is the first drug in its class approved for Parkinson's disease in the United States.
Peso Molecular
384,4000 g/mol
LogP
2,50
TPSA
76,90 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O
InChI
InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
Molecular Formula
C20H24N4O4
HBD / HBA
- / 5
Ligações Rotacionáveis
6
Átomos Pesados
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This adenosine A2A receptor antagonist is used as an add-on therapy in adults with Parkinson's disease experiencing wearing-off episodes with levodopa treatment. It reduces the time patients spend in an "off" state (with return of Parkinson's symptoms) by modulating dopaminergic signaling through the indirect pathway of the basal ganglia. It is the first drug in its class approved for Parkinson's disease in the United States.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Istradefylline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL431770. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311037. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="istradefylline"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/istradefylline/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/istradefylline/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/istradefylline/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="istradefylline"></drugfyi-drug>